The BNIP3 subfamily of BH3-only proteins consists of BNIP3 and BNIP3-like (BNIP3L) proteins. These proteins form stable homodimerization complexes that localize to the outer membrane of the mitochondria after cellular stress. This promotes either apoptotic or nonapoptotic cell death such as autophagic cell death. Although the mammalian cells contain both members of this subfamily, the genome of Caenorhabditis elegans codes for a single BNIP3 ortholog, ceBNIP3, which shares homology in the transmembrane (TM) domain and in a conserved region close to the BH3 domain of mammalian BNIP3 protein. The cell death activities of BNIP3 and BNIP3L are determined by either the BH3 domain or the C-terminal TM domain. The TM domain of BNIP3 is unique, as it is capable of autonomous stable dimerization and contributes to mitochondrial localization of BNIP3. In knockout mouse models, BNIP3L was shown to be essential for normal erythrocyte differentiation and hematopoietic homeostasis, whereas BNIP3 plays a role in cellular responses to ischemia/reperfusion injury in the heart. Both BNIP3 and BNIP3L play a role in cellular responses to stress. Under hypoxia, both BNIP3 and BNIP3L expression levels are elevated and contribute to hypoxia-induced cell death. In addition, these proteins play critical roles in disease states. In heart disease, both BNIP3 and BNIP3L play a critical role in cardiomyocyte cell death following ischemic and nonischemic injuries. In cancer, expression of BNIP3 and BNIP3L is downregulated by promoter hypermethylation or by homozygous deletion of the gene locus in certain cancers, whereas their expression was increased in other cancers. In addition, BNIP3 expression has been correlated with poor prognosis in some cancers. The results reviewed here suggest that BNIP3 and BNIP3L may be novel therapeutic targets for intervention because of their pathological roles in regulating cell death in disease states.
Introduction
The first member of this subfamily of BH3-only proteins, BNIP3 (Bcl-2/E1B-19K-interacting protein 3; initially called Nip3), was isolated by yeast two-hybrid screening using E1B-19K as the bait (Boyd et al., 1994) . BNIP3 was shown to be a mitochondrial protein that also interacted with other BCL-2 family antiapoptotic proteins, BCL-2, BCL-xL and EBV-BHRF1 (Boyd et al., 1994; Theodorakis et al., 1996) . BNIP3 resembles other BCL-2 family proteins by virtue of a characteristic mitochondrial targeting C-terminal transmembrane (TM) domain and by the presence of a BH3 domain (Yasuda et al., 1998b) . A second member of this family, BNIP3L, which shares about 55% sequence similarity to BNIP3, was identified by data bank searches (variously named BNIP3L (Matsushima et al., 1998) , B5 (Ohi et al., 1999) , BNIP3a (Yasuda et al., 1999) , NIX (Chen et al., 1999) , BNIP3h (Farooq et al., 2001) , hereafter called BNIP3-like). Similar to BNIP3, BNIP3L (designated B5) was also identified in a two-hybrid screen with the E1B-19K bait (Ohi et al., 1999) . BNIP3 maps in human chromosome 10q26.3, whereas BNIP3L maps in 8p21. Homology searches of the Caenorhabditis elegans sequences identified a BNIP3 ortholog with 21% aminoacid homology to BNIP3 in the locus of CEC14F5.1 (Yasuda et al., 1998a; Cizeau et al., 2000) . The homology between ceBNIP3 and the mammalian members includes a highly conserved 19-amino-acid sequence encompassing the BH3 domain and the TM domain ( Figure 1 ). However, the BH3 domain of ceBNIP3 is somewhat divergent from those of the mammalian BNIP3 and BNIP3L. These proteins are also characterized by the presence of PEST sequences at the N-terminal region. Data bank analysis has revealed conservation of BNIP3-related sequences in most animal species (Aouacheria et al., 2005) . Unlike most other BH3-only proteins, the cell death activities of BNIP3 and BNIP3L are controlled by the BH3 domain as well as by the TM domain causing both apoptotic and necrotic cell death (Chen et al., 1997; Yasuda et al., 1998b; Vande Velde et al., 2000; Kubasiak et al., 2002 ). It appears that BNIP3 and BNIP3L may constitute important mitochondrial sensors for various stress stimuli. The expression of BNIP3 is strongly activated by hypoxia and is the direct transcriptional target for hypoxia-inducible factor (HIF)-1a (Bruick, 2000; Kothari et al., 2003) . Although BNIP3L was shown to be activated by hypoxia (Sowter et al., 2001; Fei et al., 2004) , hypoxia-independent activation has also been observed in specific cell types such as cardiomyocytes (Yussman et al., 2002; Galvez et al., 2006) . Both BNIP3 and BNIP3L appear to play important roles in cell death induced by ischemic stress of cardiomycytes and neuronal cells. In addition, they also appear to play a role in tumor progression as well as in tumor suppression. This review summarizes the critical aspects of the biological activities of BNIP3 subfamily proteins.
Domains of BNIP3 family members

BH3 domain
BNIP3 was shown to possess a functional BH3 domain based on mutational analysis and domain-substitution studies (Yasuda et al., 1999) . First, a deletion within the BH3-like domain of BNIP3 was shown to abolish the interaction of BNIP3 with E1B-19K and BCL-2. Second, a 16-amino-acid region of BNIP3 corresponding to the 16-amino-acid a-helical region of BCL-xL and BAK containing the BH3 domain (Sattler et al., 1997) or a 9-amino-acid region of BNIP3 corresponding to the core BH3 domain in BAX was shown to functionally substitute for the BH3 domain of BAX in the transient cell death assays and in interaction with BCL-xL. Similarly, deletion of a 7-amino-acid sequence corresponding to the core BH3 domain of BNIP3L diminished its interaction with BCL-2 and the cell death activity (Imazu et al., 1999) . The sequence of ceBNIP3 corresponding to the BH3 domain of BNIP3 and BNIP3L is divergent (Yasuda et al., 1998a; Cizeau et al., 2000) . Deletion of the BH3 domain of ceBNIP3 did not significantly alter its cell death activity in mammalian cells . Similarly, deletion of the BH3 domain in BNIP3 failed to alter its cell death activity in epithelial-derived cells . In general, the BH3 domains of BNIP3 subfamily members appear to be weak, in comparison with other strongly pro-apoptotic members of the BH3-only proteins, with regard to their affinity for pro-survival proteins and may contribute to the delayed cell death activities of these proteins. The BH3 domains of all BNIP3 family proteins contain a Trp residue instead of 110   BNIP3   1  194  119  184  164   TM  BH3  130  Cys64   BNIP3L   1  2 1 9  188  208  134 143  154  Cys93   ceBNIP3   1  2 1 0  118 129  178  201   Conserved   140 Ser/Thr-rich
Cys70
Figure 1 Domain structure of BNIP3 subfamily members. (a) The BH3 domain, the conserved domain (CD), the transmembrane domain (TM) and the conserved Cys residue implicated in stabilization of the BNIP3 homodimers are indicated. The coordinates of ceBNIP3 are based on the ORF described by Yasuda et al. (1998a) . The ORF described by Cizeau et al. (2000) contains an extra 11-amino-acid region at the N terminus. (b). The amino-acid sequence of the BH3 domain and the conserved domain are indicated. A conserved Trp residue within the BH3 domain of all BNIP3-related proteins is indicated by an asterisk. In the bottom panel, the BH3 domain of BNIP3 is compared with the BH3 domain of BAD to highlight the Ser residue. (c) The amino-acid sequences of the TM domain and the sequence elements that mediate homodimerization are shown.
D/E residues in the BH3 domain of most other BH3-only members (Aouacheria et al., 2005) . The possibility that the Trp residue may regulate selectivity in interaction with pro-survival proteins remains to be investigated. In addition, it is possible that the activity of the BH3 domain, at least in the case of BNIP3, might be regulated by phosphorylation. It should be noted that the BH3 domain of BNIP3 resembles the BH3 domain of BAD, which has been known to be phosphorylated by survival kinases such as PKA induced by growth factors (Datta et al., 2000; Zhou et al., 2000) .
TM domain
The TM domains of BNIP3 family members are unique among the various BCL-2 family members and appear to contribute to their death-promoting activity. When BNIP3 was identified, it was shown to be localized in the outer membrane of the mitochondria (Boyd et al., 1994) . Subsequently, it was shown that the C-terminal TM domain was responsible for targeting BNIP3 to mitochondria, as a BNIP3 mutant lacking the TM domain localized dispersedly throughout the cell and the BNIP3 TM conferred mitochondrial localization to GFP (Yasuda et al., 1998b) . The TM domain of BNIP3L is highly homologous to the TM domain of BNIP3 and was shown to be functionally similar (Chen et al., 1999; Imazu et al., 1999; Yasuda et al., 1999 ). Greenberg's group first reported that BNIP3, when analysed by SDS-PAGE, migrated predominantly as a 60-kDa dimer in addition to the 30-kDa monomer (Chen et al., 1997) . Deletion of the TM domain abolished dimer formation, suggesting a critical role for the TM domain in detergent-stable dimerization. The TM domain of BNIP3L (Chen et al., 1999; Imazu et al., 1999) and ceBNIP3 functioned similarly in promoting stable dimerization. The TM domains of BNIP3 and BNIP3L were also shown to mediate heterodimerization among these proteins (Ohi et al., 1999) . Owing to the high stability of BNIP3 dimers, the BNIP3 TM domain has become a favored model to study the biophysical aspects of dimerization of integral membrane proteins by lateral interactions between TM a helices (Sulistijo et al., 2003; Sulistijo and MacKenzie, 2006; Metcalf et al., 2007) . The isolated TM domain of BNIP3 was shown to dimerize strongly in membranes and in detergents (Sulistijo et al., 2003) . The BNIP3 TM domain contains a GXXXG motif, which is a critical determinant for dimerization of other membrane proteins (Russ and Engelman, 2000) . In addition, BNIP3 also contains a tandem AXXXG motif. These tandem motifs and electrostatic interactions involving an adjoining His (173) and Ser (172) have been shown to be important for stabilization of the BNIP3 dimer (Sulistijo et al., 2003; Sulistijo and MacKenzie, 2006) . The side chain of His has been proposed to hydrogen bond with the side chain of Ser across the dimer interface. These sequence features are conserved in BNIP3L. Interestingly, ceBNIP3 also contains two tandem SXXXG and GXXXG motifs.
As small residues such as Ala and Ser could substitute for the G residue (Sulistijo and MacKenzie, 2006) , it appears that the two GXXXG-related motifs present in ceBNIP3 could also contribute to stable dimerization. The conserved feature of highly stable dimerization in BNIP3 family members suggests a functional significance. However, the precise role of dimerization in the pro-death activity of BNIP3 remains unresolved.
Several studies (see below) have shown that the deletion of the entire TM domain (DTM) abolished the pro-death activity of all three members of the BNIP3 family. It is possible that this functional defect of the DTM mutants might be the result of their inability to localize in the mitochondria. It appears that the unique stable dimerization activity of BNIP3 is not critical for its cell death activity. Substitution of the TM domain of BNIP3 with the heterologous TM domain of BCL-2 that targeted BNIP3 to mitochondria as well as other cytosolic membrane locations, such as the ER, did not affect the cell death activity and the ability to heterodimerize with BCL-2 and BCL-xL . Such a chimeric construct was also shown to induce loss of mitochondrial permeability transition and increased reactive oxygen species (Kim et al., 2002 ). An aminoacid-substitution mutant in the His residue (His-Ala) of the TM domain implicated in the stabilization of BNIP3 dimers did not significantly alter the deathpromoting activity under hypoxic and acidotic conditions (Frazier et al., 2006) . However, the same mutation was shown to abolish the cell death activity of BNIP3L by another group (Kubli et al., 2008) . These authors also reported that the homodimer of BNIP3 was stabilized by the disulfide linkage mediated by a conserved Nterminal Cys (Cys64) residue. The above summarized results suggest that the TM domain of BNIP3 is important for its pro-death activity and for the specific targeting of BNIP3 to mitochondria (Figure 2) . However, the pro-death activity could not be attributed to the unique property of the BNIP3 TM domain. This conclusion was supported by the observation that substitution of the BNIP3 TM for the TM domain of the pro-survival protein EBV-BHRF1 did not diminish the pro-survival function of BHRF1 (Yasuda et al., 1998b) .
N-terminal and conserved domains
The N-terminal regions of the BNIP3 subfamily members are divergent. However, all three members of the subfamily are characterized by the presence of PEST sequences that are associated with proteins that are subjected to high turnover by proteasome-mediated degradation (Rogers et al., 1986) . Although no other notable sequence motifs in the N-terminal 49-aminoacid region of BNIP3 can be identified, it was shown to be important for heterodimerization with BCL-2 (along with the TM domain), whereas the interaction with BCL-xL was shown to require either the N-terminal or the C-terminal region . The precise mode of such interactions with BCL-2/BCL-xL remains to be resolved. Although the role of the N-terminal region of BNIP3 in cell death activity has not been examined, deletion of the N-terminal region (39 amino acids) of BNIP3L (which lacks any homology to BNIP3) was reported to enhance cell death activity (Ohi et al., 1999) .
All three members of the BNIP3 subfamily contain a highly conserved domain immediately adjacent to the BH3 domain. Although the high degree of such homology between vertebrate proteins (BNIP3 and BNIP3L) and invertebrate protein (ceBNIP3) suggests a conserved function, mutational analyses of this domain have not yielded any functional clues. Deletion of this domain along with the BH3 domain did not significantly alter the pro-cell death activity of BNIP3 in certain in vitro cell death assays .
Regulation of expression of BNIP3 family members
BNIP3 was identified as one of the most prominent hypoxia-responsive genes by subtractive hybridization studies (Bruick, 2000) . The promoter of BNIP3 was found to contain a hypoxia response element that suggested that BNIP3 was a direct target for HIF-1. This study also observed a modest (B2-fold) activation of BNIP3L under hypoxia. As no other member of the BCL-2 family was found to be activated by hypoxic stress, it was suggested that BNIP3 and BNIP3L might be key players in cell death induced under hypoxic injury such as ischemia. Subsequently, overexpression of HIF1a was shown to induce expression of BNIP3 and cell death (Guo et al., 2001) , which strengthened the conclusion that BNIP3 was a target for HIF-1a. Harris and co-workers also reported transcriptional activation of BNIP3 and BNIP3L in several carcinoma cell lines exposed to hypoxia (Sowter et al., 2001) . In these studies, the role of HIF-1a was further shown using a cell line that lacked the tumor suppressor pVHL (a negative regulator of HIF-1a) in which BNIP3 was found to be overexpressed and in which the reintroduction of pVHL reduced BNIP3 expression. In addition, Sowter et al. (2003) observed elevated expression of BNIP3 and BNIP3L in the perinecrotic regions (which result from hypoxia) of human tumors. Many subsequent reports have confirmed that BNIP3 was one of the early hypoxia-responsive genes that showed that such activation might contribute to several pathological processes such as neuronal and myocardial ischemic cell death (Kubasiak et al., 2002; Regula et al., 2002; Graham et al., 2004) . It was also suggested that hypoxia-induced tumor necrosis through BNIP3 expression may contribute to the development of certain solid tumors (see below).
In addition to HIF-1a, other transcription factors also significantly contribute to BNIP3 expression under hypoxia. The zinc-finger transcription factor, pleomorphic adenomas gene-like 2 (PLAGL2) (which is expressed in response to hypoxia or iron deficiency) was reported to activate BNIP3, resulting in apoptotic death of cultured fibroblasts and neuroblastoma cells (Mizutani et al., 2002) . The effect of PLAGL2 was shown to be independent of HIF-1, as PLAGL2 activated the BNIP3 promoter that lacked a hypoxia response element. It is possible that both HIF-1 and PLAGL2 may independently and additively activate BNIP3 during hypoxia. Although the precise site with which PLAGL2 interacts on the BNIP3 promoter has not been determined, it appears that it may interact with one of the several GC-rich boxes of the BNIP3 promoter ( Figure 3 ). While probing the mechanism of cell death in Rb null fetal liver during mouse embryo development (which experiences ischemia), Macleod and co-workers discovered that loss of pRb resulted in derepression of BNIP3 expression and non-apoptotic cell death (Tracy et al., 2007) . These results suggest a survival-promoting activity of pRb in fetal liver cells. They further identified that BNIP3 was a direct target for transcriptional repression by pRb/E2F and that pRb reduced the expression of BNIP3 during hypoxia, resulting in BNIP3-dependent autophagy and cell survival. They showed that, under non-stress conditions, the BNIP3 promoter was associated with E2F4 (a repressive member of the E2F family) and that under hypoxic stress conditions the transcription factor E2F1 bound to the BNIP3 promoter displacing E2F4. Chromatin immunoprecipitation analysis revealed that recruitment of E2F1 also accompanied recruitment of pRb resulting in reduction of the BNIP3 promoter activity, suggesting a functional cooperation between pRb and HIF-1a in reducing the level of BNIP3 expression. Thus, this study illuminates a new function for the pRb tumor suppressor in regulating the levels of BNIP3 expression under stress conditions that would be a determining factor in autophagic cell survival vs cell death. Schneider and coworkers have shown that an activity of adenovirus E1A that liberates E2F transcription factors from pRb family proteins was able to induce proliferation of adult rat cardiac myocytes and it also showed that the exogenous introduction of E2F1 through a recombinant adenovirus vector induced cell proliferation and apoptosis (Kirshenbaum et al., 1996; Agah et al., 1997) . More recently, Kirshenbaum and co-workers have shown that apoptosis induced by E2F1 was a consequence of the direct transcriptional activation of BNIP3 through E2F1 binding with the BNIP3 promoter (Yurkova et al. , 2008) . The possibility that E2F1 may function in concert with HIF-1a to activate BNIP3 in ventricular myocytes remains to be investigated. A study by Sandri and co-workers, who analysed the target genes for the transcription factor, FoxO3 (which contributes to skeletal muscle atrophy through autophagy), identified BNIP3 as a FoxO3 target gene along with other autophagy-related genes such as LC3 and certain ubiquitin ligases (Mammucari et al., 2007) . They reported the binding of FoxO3 to the promoters of BNIP3 and BNIP3L in fasting muscle cells by chromatin immunoprecipitation analysis and increased expression of BNIP3 and BNIP3L. Depletion of FoxO3 in fasting cells reduced the level of BNIP3 expression, and the transfection of FoxO3 in HEK293 cells activated expression of endogenous BNIP3, supporting the conclusion that FoxO3 activated BNIP3 in these cells. Thus, BNIP3 appears to be the direct target of transcription factors that induce apoptosis or autophagy such as PLAGL2, E2F1 and FoxO3, in addition to HIF-1. Although the expression of BNIP3 is strikingly regulated by hypoxia in tissues such as heart, it appears to be constitutive in certain tissues such as the liver and kidney (Galvez et al., 2006) . It is possible that transcription factors such as Sp1 that recognize the GC boxes of the BNIP3 and BNIP3L promoters contribute to their constitutive basal expression. In addition to transcriptional repressors such as pRb and E2F4, and hypermethylation of the Bnip3 promoter, which have been shown to downregulate Bnip3 expression, a NFkB-dependent mechanism of transcriptional silencing of Bnip3 has also been identified (Baetz et al., 2005; Shaw et al., 2006 . In contrast to the well-known transcriptional activation function of NFkB, the studies by Kirshenbaum and co-workers showed that the binding of the p65 subunit of NFkB to the Bnip3 promoter resulted in transcriptional repression in rat ventricular myocytes. The repression activity of p65 was dependent on recruitment of histone deacetylase 1. Under non-stress conditions, NFkB was found to be associated with the Bnip3 promoter, preventing association of E2F-1 to an adjacent E2F-binding site . Under hypoxia, when the level of NFkB was low, expression of Bnip3 was activated as a result of E2F-1 binding.
As mentioned above, modest activation of BNIP3L was observed when cultured cells were exposed to hypoxia (Bruick, 2000; Sowter et al., 2003) , consistent with the presence of potential hypoxia response elements in the BNIP3L promoter (Aerbajinai et al., 2003; Fei et al., 2004; Galvez et al., 2006) . However, the expression of BNIP3L appears to be more constitutive than that of BNIP3 in several cellular contexts. BNIP3, along with BAK, was identified as one of the proapoptotic target genes for the immediate-early growth response gene Egr-2 in the PTEN-induced apoptotic pathway (Unoki and Nakamura, 2003) . Exogenous expression of EGR2 was shown to directly activate BNIP3L and BAK in a variety of human cancer cells, including those harboring mutations in p53 and PTEN genes. BNIP3L can be cooperatively activated by HIF-1 and p53 under hypoxia, resulting in p53-dependent apoptosis under hypoxia (Fei et al., 2004) . In addition to HIF-1, other transcription factors have also been reported to activate BNIP3L. In cardiac myocytes, BNIP3L was shown to be activated by factors that activate PKCa through the transcription factor Sp1 (Galvez et al., 2006) . Therapeutic blockade of the activities of the TM tyrosine kinase receptors, EGFR (ErbB1) and HER-2 (ErbB2), has been reported to activate the expression of BNIP3L through the transcription factor FoxO3 (Real et al., 2005) . As pointed out above, BNIP3L was shown to be transcriptionally activated by FoxO3 in fasting muscle cells (Mammucari et al., 2007) . Interestingly, ceBnip3 has also been identified as a transcriptional target for daf-16, the worm homolog of FoxO (Murphy et al., 2003) .
In addition to the transcriptional regulation of Bnip3 and Bnip3L, the levels of transcripts of these genes were also reported to be regulated at the post-transcriptional level in some instances. In murine macrophages treated with sublethal doses of anthrax lethal toxin, there was destabilization of Bnip3 and Bnip3L mRNAs (Ha et al., 2007) . Although the mechanism of downregulation of Bnip3/Bnip3L mRNAs was not known, it was suggested that phosphorylation of proteins that regulate the mRNA levels through binding to AU-rich elements in the 3 0 -untranslated regions might play a role.
Cell death and autophagy induced by BNIP3 family members
Although BNIP3 was identified and cloned before BIK (the founding member of the BH3-only proteins), its cell death-promoting activity remained unresolved as BNIP3 overexpression in common cell lines under normal culture conditions did not result in profound changes in cell viability. Subsequent studies showed that overexpression of BNIP3 caused a delayed cell death activity (Chen et al., 1997; Yasuda et al., 1998b) . A similar cell death activity was also observed in cells transfected with BNIP3L (Imazu et al., 1999) . The cell death observed in transient transfection-based assays was shown to be dependent on the BH3 domain (Yasuda et al., 1998b; Imazu et al., 1999) or the TM domain (Chen et al., 1999; Ray et al., 2000) . Although the cell death induced by transient overexpression of BNIP3 was referred to as apoptotic in these publications, those assays were not sensitive enough to discriminate between different modes of cell death. In subsequent studies, Greenberg and co-workers observed that overexpression of BNIP3 caused a form of cell death that resembled necrosis that was not inhibited by the pancaspase inhibitor, zVAD-fmk, or the caspase agonist baculovirus p35 . Further, BNIP3-mediated cell death was observed in mouse embryo fibroblasts (MEFs) that individually lacked Apaf-1, caspase-3 and caspase-9. Ultrastructural studies of cells undergoing BNIP3-induced death revealed extensive cytoplasmic vacuoles that resembled autophagosomes.
Subsequent studies by Kondo and co-workers showed that malignant glioma cells treated with the anticancer agents, sphingolipid ceramide (Daido et al., 2004) and arsenic trioxide (Kanzawa et al., 2005) , underwent cell death that was accompanied by autophagic signatures, such as association of the microtubule-associated protein lightchain 3 (LC3) in autophagosomes. Several recent studies have further substantiated that one mode of BNIP3-induced cell death may involve autophagy (HamacherBrady et al., 2007; Tracy et al., 2007; Azad et al., 2008; Mammucari et al., 2008; .
The evidence linking BNIP3 to autophagy and autophagic cell death appears to be strong. Although these activities of BNIP3 appear to be related to strong mitochondrial localization of BNIP3, the precise mechanism by which BNIP3 promotes autophagy and autophagic death remains to be clarified in detail. Similar to BNIP3, other BH3-only members and BH3 mimetics have also been reported to induce autophagy and autophagic death (Yanagisawa et al., 2003; Abedin et al., 2007; Maiuri et al., 2007; Rashmi et al., 2008; Zhaorigetu et al., 2008) . The pharmacological BH3 mimetic, ABT737, was shown to competitively inhibit interaction of Beclin-1 with BCL-2/BCL-xL (Maiuri et al., 2007) . In cotransfection experiments, BNIP3 was shown to compete with Beclin-1 for interaction with BCL-2 . These results suggest that liberating Beclin-1 from BCL-2/BCL-xL may be one of the mechanisms by which BH3-only members, including BNIP3, may promote autophagy. As loss of mitochondrial permeability transition appears to induce autophagy (Elmore et al., 2001) , BNIP3 may also induce autophagy indirectly as a consequence of such mitochondrial injury. It appears that prolonged BNIP3 expression or acute overexpression beyond an autophagic survival threshold may result in autophagic cell death. It was recently reported that prolonged exposure of several apoptosis-competent cancer lines to hypoxia induced autophagy and cell death in a BNIP3-dependent manner (Azad et al., 2008) . The onset of autophagy and resulting cell death was dependent on BNIP3 as depletion of BNIP3-reduced autophagy. These results suggest that activation of BNIP3 by hypoxia alone could contribute to autophagy and autophagic death, independent of apoptosis (Figure 2) .
In neonatal rat cardiac myocytes exposed to hypoxia and acidotic conditions, BNIP3 was shown to cause a form of cell death that resembled apoptosis, as the plasma membrane remained intact without significant loss of ATP accompanied by the opening of the mitochondrial permeability transition pore and extensive DNA laddering (Kubasiak et al., 2002) . Nonetheless, such cell death was shown to be independent of caspase activation. Although the role of BH3 domain in this unique mode of cell death was not examined, the TM domain was shown to be essential. In a study that involved a cardiac myocyte cell line exposed to ischemia and reperfusion (I/R) injury, an apoptotic cell death was suppressed by overexpression of the dominant-negative version of BNIP3 (BNIP3DTM), or by shRNAmediated down-regulation of BNIP3 or zVAD-fmk 
/Bak
À/À double-knockout MEFs revealed that BNIP3-mediated cell death was dependent on these proapoptotic BCL-2 family members (Kubli et al., 2007) . Overexpression of BNIP3 in wt MEFs caused rapid loss of mitochondrial TM potential, increased production of reactive oxygen species and cell death. These activities of BNIP3 were deficient in Bax/Bak double-knockout MEFs and were observed on reintroduction of Bax and Bak, suggesting a Bax/Bak dependency for BNIP3 cell death activity. Similar to other prototypic proapoptotic stimuli, overexpression of BNIP3 was shown to induce conformational activation of BAX and BAK, leading to permeabilization of the mitochondrial outer membrane, release of cytochrome c and mitochondrial fragmentation. Although the overall features of BNIP3-induced cell death in MEFs resembled features common to caspase-dependent and -independent cell death, the specific involvement of caspases was not examined in these studies. Thus, it appears that BNIP3 may induce both apoptotic and non-apoptotic cell death, depending on the context of cell death stimulation or on the cell types studied. However, it also appears that the extent of apoptotic cell death induced by BNIP3 and BNIP3L is generally weaker than that induced by BH3-only members such as BIK and BIM.
BNIP3 and BNIP3L in cancer
A hallmark of solid tumors is that they are poorly oxygenated in the interior of the tumor mass because of insufficient vascularization. The hypoxic regions of the tumors are characterized by excessive apoptotic and necrotic cell death. It is widely believed that the hypoxic stress in the tumor microenvironment contributes to the evolution of malignant tumor cells with increased invasive and angiogenic potentials. Tumor cells under hypoxic conditions experience a high incidence of genome instability and increased mutation rate (Reynolds et al., 1996) . Among the tumor cells in the hypoxic area, variant tumor cells often arise and are resistant to apoptosis (Graeber et al., 1996) . Tumor hypoxia has been reported to be a negative prognostic factor in a number of tumor sites. Both clinical and experimental studies have suggested a positive correlation between tumor hypoxia and increased metastatic efficiency and resistance to radiotherapy and chemotherapy, resulting in tumor relapse. Although several cellular factors are upregulated by hypoxia, BNIP3 may significantly contribute to the oncogenic evolution of cancer cells. In situ hybridization studies have revealed that BNIP3 was highly expressed in the perinecrotic regions of human breast tumors compared with normal tissues (Sowter et al., 2001) . In an analysis of clinical samples of ductal carcinoma in situ of the breast, expression of Bnip3 was found to be associated with high-grade tumors whereas the expression of Bnip3L did not reveal such a correlation (Sowter et al., 2003) . These studies suggest that expression of Bnip3 might be associated with high-grade and necrotic phenotype of breast ductal carcinoma in situ. An immunohistochemical analysis of more than 100 nonsmall-cell lung cancer clinical samples revealed that expression of BNIP3 was closely linked with HIF-1a and was strongly correlated with poor prognosis (Giatromanolaki et al., 2004) .
Expression of BNIP3 was also found to be associated with expression of other hypoxia-induced growth factors such as vascular endothelial growth factor, basic fibroblast growth factor and platelet-derived growth factor (Giatromanolaki et al., 2004) . Although it is counterintuitive why a gene that promotes cell death is overexpressed in high-grade tumors, it is possible that the survival-promoting activities of various cytokines induced during hypoxia may suppress the cell death activity of BNIP3 in these specific cancers. In this context, it has been shown that the cell death activity of BNIP3 is inhibited by growth factors such as EGF and IGF in epithelial cells (Kothari et al., 2003) . The conflicting signals imposed by the cell death factor (that is, BNIP3) and the survival factors (such as vascular endothelial growth factor, basic fibroblast growth factor and so on) may allow selection of tumor cells that survive chronic Bnip3 overexpression. Other regulatory mechanisms in these 'high-grade tumors' may also modulate the cell death activity of BNIP3. For example, an analysis of a number of lung cancers with the worst prognosis revealed nuclear localization of BNIP3 (Giatromanolaki et al., 2004) . Similarly, in about 80% of the primary glioblastoma multiforme tumors, BNIP3 was predominantly localized in the nucleus (Burton et al., 2006) . Such nuclear localization of BNIP3 during tumor progression may constitute another mechanism by which tumors under hypoxia may overcome BNIP3-induced cell death. This notion is consistent with the results that elevated levels of BNIP3 expression in invasive carcinoma of the breast was associated with good survival outcome and shorter disease-free survival in pre-invasive DISC (Tan et al., 2007) .
Inactivation of BNIP3 expression may constitute a critical step in tumor progression in several human cancers such as the cancer of the pancreas. An analysis of pancreatic adenocarcinomas and pancreatic cancer cell lines revealed that the expression of BNIP3 was inactivated by hypermethylation of the BNIP3 promoter (Okami et al., 2004; Abe et al., 2005) . In nine of nine pancreatic carcinomas, BNIP3 was downregulated compared with normal pancreatic tissues despite upregulation of other hypoxia-responsive genes such as glucose transporter-1 and insulin-like growth factorbinding protein 3 (Okami et al., 2004) . The BNIP3 promoter was found to be methylated in the CpG island near the transcription-initiation site of the BNIP3 promoter. In pancreatic cancer cell lines, hypoxiainducible BNIP3 expression was restored by treatment with the demethylating agent 5-aza-deoxycytidine (Okami et al., 2004; Abe et al., 2005) . A microarray analysis revealed that, in certain pancreatic ductal adenocarcinomas, downregulation of BNIP3 was correlated with upregulation of S100 family proteins such as S100A2 and S100A4 (Mahon et al., 2007) . Specific depletion of the metastasis-promoting member of the S100 family, S100A4, activated BNIP3 expression, resulting in apoptosis of pancreatic cancer cell lines. An apparent need to downregulate BNIP3 during tumor progression was shown in studies that investigated the link between BNIP3 expression and metastasis of mouse breast cancer cell lines (Manka et al., 2005) . Depletion of BNIP3 in a non-metastatic cell line (4T07) blocked cell death and increased clonogenic survival under hypoxic culture conditions in vitro, besides increased tumor size, enabling metastasis to multiple organs in mice injected with the depleted cells (Manka and Millhorn, 2006) . A report by these authors also raised the possibility that, in metastatic cells that still expressed residual levels of BNIP3, the activity of BNIP3 might be impaired as a result of post-translational modifications such as the addition of O-linked N-acetylglucosamine (Manka and Millhorn, 2006) . The effect of post-translational modifications, including O-linked N-acetylglucosamine on BNIP3 function, remains to be investigated. The above report highlights the need for a systematic investigation on the role of post-translational modification of BNIP3 on its cell death activity. Thus, it appears that transcriptional silencing of BNIP3 through promoter hypermethylation or through upregulation of transcriptional regulators such as S100A4 or post-translational protein modifications may play a critical role in pancreatic cancer progression and that BNIP3 may be a tumor suppressor in the pancreas. Analyses of several pancreatic cancer cell lines revealed that their relative chemoresistance to first-line antipancreatic cancer drugs such as gemcitabine and 5-fluorouracil was linked to the lack of BNIP3 expression (Akada et al., 2005; Erkan et al., 2005; Ishida et al., 2007) , and loss of BNIP3 expression also correlated with worsened prognosis of pancreatic ductal adenocarcinomas (Erkan et al., 2005) . These results suggest that anticancer drugs that may activate expression of BNIP3 in these cancers might constitute an important treatment modality.
In addition to pancreatic cancers, BNIP3 was also reported to be downregulated by promoter hypermethylation and histone deacetylation in colorectal cancers (Murai et al., 2005b; Bacon et al., 2007) , gastric cancers (Murai et al., 2005b) and hematopoietic cancers (Murai et al., 2005a) . Reversal of these epigenetic marks by treatment with 5-aza-deoxycytidine or trichostatin A resulted in re-expression of BNIP3 and conferred hypoxia-inducible cell death in cancer cell lines. These results reinforce the notion that downregulation of BNIP3 is an important epigenetic mechanism that contributes to tumor progression in multiple cancers. However, it raises the question why BNIP3 expression was associated with high-grade pre-invasive cancers of the breast. As in the case of pancreatic cancers (Erkan et al., 2005) , downregulation of BNIP3 expression or functional sequestration by nuclear localization may be a late and essential stage in tumor progression that may confer survival advantage to invasive cancers.
In contrast, during early pre-invasive stages, BNIP3 upregulation as a result of hypoxic tumor environment and chronic tumor necrosis may drive tumor progression. A detailed discussion on the role of BNIP3 in multiple human cancers can also be found elsewhere (Mellor and Harris, 2007) .
Our understanding of the role of BNIP3L in cancer is somewhat limited compared with that of BNIP3. Certain studies with human tumor cell lines and clinical samples suggest that BNIP3L may function as a tumor suppressor. An reverse transcription PCR analysis of several lung cancer cell lines and clinical samples showed downregulation of Bnip3L (Sun et al., 2004) . A gene expression profiling study that involved implantation of human pancreatic carcinoma cells in severe combined immunodeficiency mice indicates that BNIP3L was downregulated in the liver metastases and tumor invasion front of the tumor compared with primary tumors (Niedergethmann et al., 2007) . A genome-wide analysis of CpG methylation in human hepatocellular carcinomas identified selective inactivation of BNIP3L, and BNIP3 was correlated with poor prognosis (Calvisi et al., 2007) . A genome-wide Gene Chip (GeneChip 500K) analysis of prostate cancer cell lines and clinical samples revealed homozygous deletion of BNIP3L (Liu et al., 2008) . Although the above reports suggest that downregulation of BNIP3L might be important for tumor progression, in addition to downregulation of other tumor suppressor genes, the specific involvement of BNIP3L was not investigated. A convincing study by El-Deiry and co-workers indicated that Bnip3L was a transcriptional target for the tumor suppressor p53 under hypoxia (Fei et al., 2004) . Interestingly, other known pro-apoptotic p53 targets, such as Puma, Bax and p21, were not induced under hypoxia. Specific depletion of BNIP3L in a non-tumorigenic human osteosarcoma (U2OS) conferred tumorigenic property in mouse xenografts. These studies also revealed that BNIP3L contributed to the p53-dependent tumor suppression of U2OS cells. More studies would be required to ascertain whether BNIP3L plays a tumorpromoting role in early stages of tumor development, similar to BNIP3.
BNIP3 and BNIP3L in cell differentiation
Gene expression profiling studies have identified an increase in BNIP3 expression during differentiation of rat oligodendrocytes (Itoh et al., 2003) . Interestingly, the increase in BNIP3 occurred in parallel with BCL-xL, suggesting that BNIP3 and BCL-xL may simultaneously regulate cell survival and cell death during differentiation. Upregulation of BNIP3 was also reported during mouse chondrocyte differentiation (Chen et al., 2005) . In the chondrocyte system, the increase in BNIP3 expression during late stages of differentiation was also accompanied by other genes implicated in cell proliferation. In human umbilical cord and bone marrow mesenchymal stem cells (which exist under hypoxic environment and differentiate into multiple cell lineages), BNIP3 and the cytokine, vascular endothelial growth factor, were prominently expressed in response to hypoxia (Martin-Rendon et al., 2007) . Immunohistochemistry analysis of several hypoxia-responsive markers during osteoclast differentiation also revealed upregulation of BNIP3 and vascular endothelial growth factor (Knowles and Athanasou, 2008) . Although these reports suggest a role for BNIP3 (in concert with certain survival factors) in cell differentiation, the precise role of BNIP3 in this process remains to be investigated.
In contrast, genetic studies using Bnip3L À/À mouse model indicate that BNIP3L plays an important role in erythrocyte differentiation. Although BNIP3L is constitutively expressed in several tissues, a gene profiling study indicated that expression of BNIP3L and BCL-xL was increased during erythropoietin-induced differentiation of human erythroblasts (Aerbajinai et al., 2003) . Bnip3L null mice showed anemia accompanied by striking enlargement of spleen and erythroblast hyperplasia in the spleen and bone marrow (Diwan et al., 2007a) . These results suggest that the accumulation of erythroblasts in the absence of BNIP3L might be the consequence of reduced cell death. This conclusion was supported by in vitro studies in which the erythroid cells cultured from the spleen of Bnip3L null mice were shown to be hypersensitive to erythropoietin treatment (which activates BCL-xL-dependent survival signaling) and resistant to multiple cell death stimuli. Thus, these studies reveal that BNIP3L-mediated cell death that opposes the erythropoietin-induced erythroblast survival was important for normal erythrocyte production in conjunction with pro-survival proteins such as BCL-xL. The same group of investigators also showed that the erythrocytes from Bnip3L À/À mice were morphologically abnormal, suggesting the requirement of BNIP3L for the maintenance of cell number and for the elimination of abnormal erythrocytes during erythropoiesis (Diwan et al., 2008a) . Erythroid cells undergo selective elimination of nuclei and organelles during terminal differentiation (Holm et al., 2002) . BNIP3L was shown to be essential for the clearance of mitochondria during the terminal stage of erythrocyte maturation (Schweers et al., 2007) . BNIP3L was shown to mediate this process through mitochondrial autophagy (Sandoval et al., 2008; Zhang and Ney, 2008) . This activity was linked to the ability of BNIP3L to induce loss of DCm that resulted in mitochondrial sequestration in autophagasomes. As defective autophagy is linked to anemia in humans (Kent et al., 1966) , extrapolation of the results obtained with the Bnip3L
À/À mouse model should provide valuable information for intervention with this disorder.
BNIP3 and BNIP3L in cardiomyocyte death
Death of cardiomyocytes following ischemic and nonischemic injury has been shown to contribute to heart failure (Narula et al., 1996; Olivetti et al., 1997) . Both BNIP3 and BNIP3L have been prominently implicated in cardiomyocyte elimination as a result of these injuries. Acute ischemia has been shown to upregulate BNIP3 expression and its insertion in the mitochondrial membrane (Regula et al., 2002; Graham et al., 2004) . Expression of the dominant-negative form of BNIP3 (BNIP3DTM) inhibited myocyte death and prevented membrane insertion of endogenous BNIP3 (Regula et al., 2002) , suggesting a direct involvement of BNIP3. Further, transduction of a cell-permeable version of BNIP3DTM (tagged with the HIV-1 Tat peptide) into whole heart conferred protection against I/R injury and improved cardiac function (Hamacher-Brady et al., 2007) . In addition to hypoxia-mediated transcriptional activation of BNIP3, the acidotic condition that occurs during ischemia was also reported to contribute to BNIP3-dependent death of myocytes (Graham et al., 2004) . A feature of myocardial infarction is the ischemic injury that is followed by sudden reoxygenation (known as I/R) that exacerbates the damage to the myocardium because of the oxidation of proteins and generation of reactive oxygen species. A recent report has indicated that BNIP3 was 'activated' through enhanced homodimerization mediated by the TM domain and a conserved N-terminal Cys residue (Cys64) and membrane insertion, suggesting that BNIP3 functions as a redox sensor during I/R injury (Kubli et al., 2008) . Thus, it appears that hypoxia-induced overexpression and subsequent BNIP3 activation by homodimerization and mitochondrial insertion are required for BNIP3-mediated myocyte death. This was highlighted by studies with transgenic mice in which forced cardiac overexpression of BNIP3 increased myocyte cell death (Diwan et al., 2007b) . As discussed earlier, BNIP3-induced myocyte death appears to be both autophagic as well as apoptotic. Studies with the Bnip3 À/À mouse model indicated that myocyte death following I/R was a delayed response (Diwan et al., 2007b) . The reader is directed to the chapter by Dorn and Kirshenbaum as well as a recent review (Shaw and Kirshenbaum, 2008) for a more detailed discussion on this subject.
Our current understanding of the role of BNIP3L in cardiomyocyte death is primarily based on elegant studies by Dorn and his co-workers who employed transgenic as well as knockout mouse models of BNIP3L (Yussman et al., 2002; Diwan et al., 2008b) . A microarray analysis in a genetic experimental cardiac hypertrophy mouse model (cardiac-specific overexpression of the heterotrimeric G protein, Gq, that recapitulates essential features of cardiac hypertrophy induced by pressure overload) by Dorn and co-workers revealed upregulation of BNIP3L in the myocardium (Yussman et al., 2002) . Transgenic mice that overexpressed Bnip3L in the heart died as neonates (6-7 days after birth) and showed features of cardiac hypertrophy and apoptosis. Importantly, the hearts of transgenic lines that overexpressed a splice variant of Bnip3L lacking the C-terminal 10 amino acids (a dominant-negative form of Bnip3L) were normal. Overexpression of the short isoform of Bnip3L in the double-transgenic mice delayed early Gq-mediated death and prevented the symptoms of cardiomyopathy. In contrast to the severe neonatal phenotype of the Bnip3L transgenic mice, the phenotype was mild in adults when expressed from an inducible promoter (Syed et al., 2004) . However, the adult phenotype was severe when combined with Gq overexpression (which by itself showed a mild adult phenotype), suggesting a synergy between specific hypertrophic factors that influence post-natal cardiac growth and factors such as BNIP3L that regulate cardiomyocyte cell death in heart failure. Cardiacspecific deletion of Bnip3L by Cre-mediated deletion provided a high degree of protection against cardiomyopathies induced by Gq overexpression or by pressure overload (Diwan et al., 2008b) . These results suggest that cell death mediated by BNIP3L is a critical determinant in hypertrophic heart failure. Thus, the results from the animal models suggest that BNIP3 and BNIP3L may be important therapeutic targets in myocardial salvage during pathological heart failures. It remains to be determined whether BNIP3L also becomes activated in adult hearts during pathological stimuli that lead to heart failure. The animal models generated by the Dorn's group would also be valuable to study interesting questions, such as the factors that restrain cell death activity in adult hearts and the mode of BNIP3L activation.
Role of BNIP3 family in other diseases and pathological cell death
Attenuation of BNIP3's ability to induce cell death has been implicated in inducing synovial hyperplasia in rheumatoid arthritis. BNIP3 is upregulated in synoviocytes, likely because of hypoxia present in arthritic joints, and plays a role in the pathogenesis of arthritis (Kammouni et al., 2007) . Under hypoxic conditions, fibroblast-like synoviocytes in culture induced BNIP3 expression, which resulted in BNIP3-induced cell death. However, BNIP3 upregulation in synoviocytes from rheumatoid arthritis patients failed to induce cell death. This is likely because of the presence of pro-inflammatory cytokines in rheumatoid arthritis patients as treatment with tumor necrosis factor-a and interleukin-1b blocked BNIP3-induced cell death in fibroblast-like synoviocytes (Kammouni et al., 2007) .
BNIP3 has been shown to play a role in neuronal cell death after a stroke. BNIP3 is upregulated in neurons after focal brain ischemia in a rat model of stroke and in cultured primary neurons exposed to hypoxia. After blockage of the middle cerebral arteries for 48 h, BNIP3 was expressed in both the cytoplasm and the nuclei. Furthermore, inhibition of BNIP3 by small-interfering RNA protected the neurons from hypoxia-induced cell death. Nuclear localization of BNIP3 has also been found in neurons in response to ischemia. Moreover, neurons that had higher levels of BNIP3 in the nucleus were more resistant to cell death, but the mechanism of this localization is still unknown (Schmidt-Kastner et al., 2004).
BNIP3 has also been implicated to play a role in neuronal cell death in Alzheimer's disease. Amyloid b-plaques are a hallmark of Alzheimer's disease that can induce caspase-independent cell death in neurons. Amyloid-b treatment of cultured rat cortical neurons resulted in an increase in BNIP3 expression through HIF-1a stabilization. Knockdown of BNIP3 blocked amyloid-induced cell death . This implicates BNIP3 in neuronal cell death in Alzheimer's disease. The role of BNIP3L is less well understood in this disease and should be the focus of future research.
Both BNIP3 and BNIP3L have been shown to play a role in macrophage cell death induced by anthrax lethal toxin (Ha et al., 2007) . A genome-wide analysis of transcripts in murine macrophages that were spontaneously resistant to the toxin showed downregulation of mRNAs for Bnip3 and Bnip3L compared with susceptible cells. Overexpression of BNIP3 and BNIP3L in resistant cells conferred toxin sensitivity. Inhibition of the p38 mitogen-activated protein kinase pathway by the toxin was linked to mRNA destabilization of these genes. As pharmacological inhibitors of p38 resulted in resistance to the toxin, the use of such inhibitors was suggested as an adjunctive therapy for anthrax toxemia, in addition to antibiotic regimens against Bacillus anthracis.
Conclusion
BNIP3 is now recognized as one of the most prominent hypoxia-activated genes. The role of hypoxia in the upregulation of BNIP3L appears to be context dependent. This mode of regulation has led to a significant body of investigation on the role of these molecules in hypoxia-modulated pathologies such as cancer and cardiomyopathies. In cancer, they appear to function as tumor promoters during the development of solid tumors that experience hypoxic environment and chronic tumor necrosis. However, they function as tumor suppressors during the tumor-progression phase. There is also strong evidence linking them to mitochondrial homeostasis and mitochondrial elimination during erythrocyte differentiation. Both BNIP3 and BNIP3L appear to mediate their function through autophagy and apoptosis-dependent mechanisms. The mechanisms by which they mediate cell death still remain to be clarified in detail. Future studies will be required to elucidate the role of different signaling pathways and post-translational modifications of BNIP3 and BNIP3L that modulate their activity. The mouse knockout models have proved valuable in elucidating the roles of BNIP3 and BNIP3L in cardiomyopathies and erythrocyte differentiation. These animal models would be expected to be important for future investigations on the role of these proteins in oncogenesis and in evaluation of potential therapeutic molecules.
